|
1）Kim E, Abdel-Wahab O. Focus on the epigenome in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2013; 2013: 538-44
|
|
|
|
2）Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391-405
|
|
|
|
|
|
3）Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379-90
|
|
|
|
|
|
4）Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014; 123: 2220-8
|
|
|
|
|
|
5）Mullally A, Lane SW, Brumme K, et al. Myelopro-liferative neoplasm animal models. Hematol Oncol Clin North Am. 2012; 26: 1065-81
|
|
|
|
|
|
6）Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015; 43: 599-603
|
|
|
|
|
|
7）Ko M, An J, Pastor WA, et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev. 2015; 263: 6-21
|
|
|
|
|
|
8）Kameda T, Shide K, Yamaji T, et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood. 2015; 125: 304-15
|
|
|
|
|
|
9）Chen E, Schneider RK, Breyfogle LJ, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015; 125: 327-35
|
|
|
|
|
|
10）Vainchenker W, Plo I. TET2 loss, a rescue of JAK2V617F HSCs. Blood. 2015; 125: 212-3
|
|
|
|
|
|
11）Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015; 372: 601-12
|
|
|
|
|
|
12）Sashida G, Shide K, Shimoda K, et al. Ezh2 loss accelerates JAK2V617F-driven primary myelofibrosis. Blood. 2013; 122: 110
|
|
|
|
|
|
13）Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20: 1472-8
|
|
|
|
|
|
14）Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371: 2488-98
|
|
|
|
|
|
15）Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371: 2477-87
|
|
|
|
|
|
16）Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44: 1179-81
|
|
|
|
|
|
17）Meldi KM, Figueroa ME. Cytosine modifications in myeloid malignancies. Pharmacol Ther. 2015; 152: 42-53
|
|
|
|
|
|
18）Scourzic L, Mouly E, Bernard OA. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 2015; 7: 9
|
|
|
|
|
|
19）Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myelo-proliferative neoplasms. Blood. 2010; 115: 2003-7
|
|
|
|
|
|
20）Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27: 1861-9
|
|
|
|
|
|
21）Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012; 26: 475-80
|
|
|
|
|
|
22）Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12: 599-612
|
|
|
|
|
|
23）Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015; 126: 790-7
|
|
|
|
|
|
24）Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015; 27: 502-15
|
|
|
|
|